In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Michael Thurn, PhD, Managing Director and CEO of Neurizon Therapeutics, a company focused on advancing treatments for neurodegenerative diseases, including ALS, with expansion efforts in Alzheimer’s, Parkinson’s, Huntington’s and others.
With over 25 years of experience in biotech innovation, entrepreneurship and leadership and broad experience in drug discovery, development, regulation and commercialization, Dr. Thurn shares his vision for advancing next-generation therapies for neurodegenerative diseases.
Dr. Thurn has led a variety of FDA lnvestigational New Drug (IND) applications across a range of therapeutic areas, and the evaluation of drugs and vaccines for registration in Australia as a part of the Drug Safety Evaluation Branch (DSEB) of the Therapeutics Goods Administration (TGA).
Dr. Thurn co-founded MARP Therapeutics and held roles at companies including Botanix, Mimetica, Spinifex, Cytopia, Xenome and Novogen.
Tune in to hear Dr. Thurn discuss Neurizon’s strategic pipeline, clinical development efforts, as well as his global experience spanning drug discovery, regulatory affairs and capital markets.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN